Two CGM assessment periods were conducted
10.1016/j.biopha.2021.112154 3 Abdel-DaimM.DawoodM
They are not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
All of these agents increase bleeding risk which can cause anemia by loss of red blood cells
Immune-modulating peptides may influence angiogenesis, fibrosis, or tumor biology, requiring indication-specific risk assessment
149 Moreover, Baggio et al 150 established cardiomyocyte conditional GLP-1R (Glp1r CM-/- ) and HCN4 knockout mice models, and found that treatment with both Liraglutide and lixisenatide elevated HR in vivo in the wild types, and attenuated in Glp1r CM-/- mice, which could be blocked by a -adrenoceptor antagonist